ReviewCurrent pharmaceutical biotechnology2015
Scalable downstream strategies for purification of recombinant adeno- associated virus vectors in light of the properties.
Review in Current pharmaceutical biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- rAAV production cost analysis: Indication-specific cost per dose and reduction strategies.Gene therapy · 2026Article
- Systemic AAV-hInternational journal of molecular sciences · 2026Article
- Characterization of difficult-to-remove host cell proteins in adeno-associated virus downstream processing.Molecular therapy. Methods & clinical development · 2025Article
- Improving AAV Production Yield and Quality for Different Serotypes Using Distinct Processing Methods.ACS omega · 2025Article
- Chromatography in Downstream Processing of Recombinant Adeno-Associated Viruses: A Review of Current and Future Practises.Biotechnology and bioengineering · 2025Review
- Review
- Consecutive Affinity and Ion-Exchange Chromatography for AAV9 Vectors Purification.Biomedicines · 2025Article
- Recent Advances in Therapeutics and Manufacturing Processes of Recombinant Adeno-Associated Virus for the Treatment of Lung Diseases.Current gene therapy · 2025Review
- A Novel Method for Separating Full and Empty Adeno-Associated Viral Capsids Using Ultrafiltration.Membranes · 2024Article
- Therapeutic Application and Structural Features of Adeno-Associated Virus Vector.Current issues in molecular biology · 2024Review
- Hybrid modeling of an ultracentrifugation process for separation of full and empty adeno-associated virus particles.Bioprocess and biosystems engineering · 2024Article
- Partial genome content within rAAVs impacts performance in a cell assay-dependent manner.Molecular therapy. Methods & clinical development · 2023Article
- Affinity and Pseudo-Affinity Membrane Chromatography for Viral Vector and Vaccine Purifications: A Review.Membranes · 2023Review
- Efficient adeno-associated virus serotype 5 capture with affinity functionalized nanofiber adsorbents.Frontiers in bioengineering and biotechnology · 2023Article
- Biophysical Characterization of Adeno-Associated Virus Vectors Using Ion-Exchange Chromatography Coupled to Light Scattering Detectors.International journal of molecular sciences · 2022Article
- Continuous Affinity Purification of Adeno-Associated Virus Using Periodic Counter-Current Chromatography.Pharmaceutics · 2022Article
- Characterization of AAV-mediated dorsal root ganglionopathy.Molecular therapy. Methods & clinical development · 2022Article
- rAAV Production and Titration at the Microscale for High-Throughput Screening.Human gene therapy · 2022Article
- Process improvement of adeno-associated virus (AAV) production.Frontiers in chemical engineering · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinant adeno-associated virus (rAAV) vector is one of the promising delivery tools for gene therapy. Currently, hundreds of clinical trials are performed but the major barrier for clinical application is the absence of any ideal large scale production technique to obtain sufficient and highly pure rAAV vector. The large scale production technique includes upstream and downstream processing. The upstream processing is a vector package step and the downstream processing is a vector purification step. For large scale downstream processing, the scientists need to recover rAAV from dozens of liters of cell lysate or medium, and a variety of purification strategies have been developed but not comprehensively compared till now. Consequently, this review will evaluate the scalable downstream purification strategies systematically, especially those based on the physicochemical properties of AAV virus, and attempt to find better scalable downstream strategies for rAAV vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.